Regeneron's Livsayis becomes the first and only siRNA therapy approved by the FDA for generalized myasthenia gravis, offering four subcutaneous doses a year.
Primary analysis from a potentially pivotal trial of Ordspono ® (odronextamab) in patients with R/R marginal zone lymphoma (MZL) to be shared in an oral presentation, part of a clinical development program evaluating Ordspono across a broad spectrum of lymphoma settings New data on Lynozyfic ® (linvoseltamab) in R/R systemic light chain (AL) amyloidosis also to be shared in an oral presentation, also part of a clinical development program evaluating Lynzoyfic across a broad spectrum of multiple myeloma settings and precursor conditions Additional presentations across a broad range of programs highlight next wave of innovation in blood disorders TARRYTOWN, N.Y., Nov. 19, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced new and updated data from its hematology portfolio and pipeline will be shared across 14 abstracts at the American Society of Hematology (ASH) 2026 Annual Meeting, taking place from December 12-15 in New Orleans.
Approval based on Phase 3 NIMBLE results demonstrating rapid, deep and sustained disease control that is maintained throughout three-month dosing intervals
REGN gains EC approval for flexible Libtayo dosing across six cancer indications, potentially improving patient convenience and strengthening its oncology business.
Regeneron Pharmaceuticals NASDAQ: REGN expects its three largest growth drivers to continue supporting revenue growth, while planning higher research and development spending and preparing for a specialty drug launch, executives said at the Jefferies Healthcare Conference.
Banco Santander S.A. boosted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 6.4% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 54,756 shares of the biopharmaceutical company's stock after purchasing an additional 3,277 shares during the quarter.